Goldman Sachs Reinstates Buy on IOVA with $15 Target

Goldman Sachs has reinstated its coverage of Iovance Biotherapeutics (IOVA) with a Buy rating and a price target of $15. The investment bank highlighted improving operational efficiencies related to the launch of IOVA's Amtagvi product, which could lead to enhanced gross margins and growth potential.

Iovance's current Price-to-Sales ratio stands at 12.9, slightly above its historical median of approximately 11.0. This elevated P/S multiple reflects optimism about the company's ability to scale its novel Amtagvi therapy and improve operational efficiencies. However, IOVA remains unprofitable, making earnings-based valuation metrics irrelevant.

The firm's GF Score is 32 out of 100, indicating modest overall fundamentals with strengths in financial stability but significant weaknesses in profitability. Iovance's strong liquidity ratios and low bankruptcy risk are major positives, but its persistent losses and negative margins remain a concern.